Cargando…
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)
BACKGROUND & AIMS: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to non-significant, is a metric to evaluate the robustness of randomized controlled trials (RCTs). We...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326696/ https://www.ncbi.nlm.nih.gov/pubmed/37425214 http://dx.doi.org/10.1016/j.jhepr.2023.100755 |